"possibly holding the most valuable IP and pipelines in Immuno-Oncology (and other Immuno disciplines) around".
And as usual, nobody knows it but the select few here. Not management of the company and not anybody on Wall Street. WE ARE AT 39 CENTS! Management won't buy!